ArticleJHLT open2026
Guideline directed-medical therapy for heart failure within 3 months post LVAD implant and rehospitalization.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guideline-directed medical therapy (GDMT) is the foundation of pharmacologic management in HF with reduced ejection fraction offering mortality and morbidity benefits. GDMT use in patients supported by durable LVADs remains inconsistent. Methods: This is a retrospective, non-interventional, single-center cohort study conducted in adult patients (≥18 years) who underwent durable LVAD implantation between January 2009 and October 2024. GDMT was defined as the prescription of at least three of the following medication classes: beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), MRAs, and SGLT2i. Patients were divided into two groups GDMT group: ≥3 GDMT and Non-GDMT group: <3 GDMT. The aim of the study was to evaluate the association between the use of GDMT within 3 months after LVAD implantation and clinical outcomes, including all-cause hospital readmission, and 12-month mortality. Results: A total of 220 patients were included in the final analysis. Of these, 49 patients (24.9%) received ≥3 classes of GDMT, while 171 patients (75.1%) received fewer than three agents. Baseline demographic and clinical characteristics showed higher creatinine, AST and lower hemoglobin on Non GDMT group. The mean age was similar between groups. Patients receiving GDMT exhibited lower NT-pro BNP levels during right heart catheterization at follow-up (1218±1025 pg/mL vs. 2051±2598 pg/mL, p=0.01). During the 12-month follow-up period, all-cause rehospitalization occurred less frequently among patients receiving GDMT (71.4% vs. 88.5%, p=0.004). In multivariable logistic regression analysis the use of GDMT within 3 months after LVAD implantation was independently associated with 62% lower odds of rehospitalization (OR 0.38, 95% CI 0.16-0.91, p=0.03). Conclusion: GDMT within 3 months post-implantation was associated with significantly fewer hospital readmissions for any cause. A favorable but non-significant trend toward lower 12-month mortality was observed. These findings support further prospective evaluation of GDMT optimization after LVAD implantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.